Editas Medicine, Inc.
EDIT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $7,543 | $3,578 | $4,658 | $30,604 |
| % Growth | 110.8% | -23.2% | -84.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $7,543 | $3,578 | $4,658 | $30,604 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $19,775 | $16,181 | $26,593 | $48,611 |
| G&A Expenses | $12,316 | $12,859 | $13,375 | $16,354 |
| SG&A Expenses | $12,316 | $12,859 | $13,375 | $16,354 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $26,082 | $40,853 | $12,232 |
| Operating Expenses | $32,091 | $55,122 | $80,821 | $77,197 |
| Operating Income | -$24,548 | -$51,544 | -$76,163 | -$46,593 |
| % Margin | -325.4% | -1,440.6% | -1,635.1% | -152.2% |
| Other Income/Exp. Net | -$569 | -$1,691 | $75 | $1,198 |
| Pre-Tax Income | -$25,117 | -$53,235 | -$76,088 | -$45,395 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25,117 | -$53,235 | -$76,088 | -$45,395 |
| % Margin | -333% | -1,487.8% | -1,633.5% | -148.3% |
| EPS | -0.28 | -0.63 | -0.92 | -0.55 |
| % Growth | 55.6% | 31.5% | -67.3% | – |
| EPS Diluted | -0.28 | -0.63 | -0.92 | -0.55 |
| Weighted Avg Shares Out | 90,090 | 84,412 | 83,055 | 82,614 |
| Weighted Avg Shares Out Dil | 90,090 | 84,412 | 83,055 | 82,614 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,831 | $2,087 | $2,716 | $1,201 |
| Interest Expense | $2,399 | $2,020 | $2,216 | $0 |
| Depreciation & Amortization | $721 | $1,834 | $1,917 | $1,381 |
| EBITDA | -$21,997 | -$49,381 | -$71,955 | -$32,980 |
| % Margin | -291.6% | -1,380.1% | -1,544.8% | -107.8% |